Rewiring macrophage immunometabolism in gouty arthritis: from metabolic checkpoints to intelligent nano-delivery
Frontiers in Pharmacology · 29.04.2026 · 17
DOI: 10.3389/fphar.2026.1794487 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Feng Xiao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Shaoyang Hospital of Traditional Chinese Medicine, Shaoyang, Hunan, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gouty arthritis (GA) is driven by NLRP3 inflammasome activation, yet its underlying metabolic mechanisms remain poorly explored. Current therapies focus on uric acid reduction and anti-inflammation, often overlooking the plasticity of macrophages controlled by metabolic reprogramming. This review systematically dissects the metabolic shifts in GA, particularly the transition from oxidative phosphorylation (OXPHOS) to glycolysis (Warburg effect) and the unique role of lipid/amino acid metabolism. We describe macrophage immunometabolism, tricarboxylic acid (TCA)cycle breakpoints, and metabolite functions, with particular emphasis on the “metabolic-epigenetic” axis (e.g., lactate conversion). We summarize emerging nanotherapeutic strategies (e.g., nanoenzymes, biomimetic carriers) precisely targeting these metabolic checkpoints. Current reviews on GA primarily focus on conventional anti-inflammatory and uric acid-lowering strategies. However, although macrophages are central drivers of the GA disease process, the mechanisms underlying the coupling of their metabolic reprogramming and polarization have not yet been fully elucidated. In particular, metabolite-mediated “metabolic-epigenetic” crosstalk, as well as how to precisely regulate these metabolic targets using emerging nanotargeting technologies, remain blind spots in current research. This paper is the first to systematically integrate these dimensions, aiming to fill this gap by exploring novel nanostrategies and future prospects for treating GA through the remodeling of macrophage immunometabolism. Targeting macrophage metabolism offers a paradigm shift for GA—from conventional symptom management to targeted disease resolution by directly inhibiting glycolytic flux and succinate accumulation, thereby repolarizing pro-inflammatory M1 macrophages into the tissue-repairing M2 phenotype.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, Shaoyang Hospital of Traditional Chinese Medicine, Shaoyang, Hunan, China.
- The First Clinical Medical College of Heilongjiang University of Chinese Medicine, Harbin City, Heilongjiang, China.
- Department of Orthopedics, Yongzhou Hospital of Traditional Chinese Medicine, Yongzhou, Hunan, China.
- Hunan University of Chinese Medicine, Changsha, Hunan, China.
- Department of Orthopedics, Longhui County Hospital of Traditional Chinese Medicine, Shaoyang, Hunan, China.
- Department of Orthopedics, Xiangtan Hospital of Traditional Chinese Medicine, Xiangtan, Hunan, China.
Zitieren
APA
Xiao, F., Zhou, X., Liu, J., Huang, K., Qin, Q., Li, C., Lu, Y., Xiong, H., Luo, X., Luo, Z., Zhang, A., & Su, W. (2026). Rewiring macrophage immunometabolism in gouty arthritis: from metabolic checkpoints to intelligent nano-delivery. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1794487
Vancouver
Xiao F, Zhou X, Liu J, Huang K, Qin Q, Li C, et al. Rewiring macrophage immunometabolism in gouty arthritis: from metabolic checkpoints to intelligent nano-delivery. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1794487
BibTeX
@article{Xiao2026,
author = {Xiao, Feng and Zhou, Xin and Liu, Jie and Huang, Kaijun and Qin, Qixiang and Li, Chengxue and Lu, Yifan and Xiong, Hui and Luo, Xiaobin and Luo, Zhiqiang and Zhang, Aitian and Su, Wenjie},
title = {Rewiring macrophage immunometabolism in gouty arthritis: from metabolic checkpoints to intelligent nano-delivery},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1794487}
}
EUVIMED